scholarly journals Central nervous system lymphoma: magnetic resonance imaging features at presentation

2012 ◽  
Vol 70 (2) ◽  
pp. 97-101 ◽  
Author(s):  
Ricardo Schwingel ◽  
Fabiano Reis ◽  
Veronica A. Zanardi ◽  
Luciano S. Queiroz ◽  
Marcondes C. França Jr.

OBJECTIVE: This paper aimed at studying presentations of the central nervous system (CNS) lymphoma using structural images obtained by magnetic resonance imaging (MRI). METHODS: The MRI features at presentation of 15 patients diagnosed with CNS lymphoma in a university hospital, between January 1999 and March 2011, were analyzed by frequency and cross tabulation. RESULTS: All patients had supratentorial lesions; and four had infra- and supratentorial lesions. The signal intensity on T1 and T2 weighted images was predominantly hypo- or isointense. In the T2 weighted images, single lesions were associated with a hypointense signal component. Six patients presented necrosis, all of them showed perilesional abnormal white matter, nine had meningeal involvement, and five had subependymal spread. Subependymal spread and meningeal involvement tended to occur in younger patients. CONCLUSION: Presentations of lymphoma are very pleomorphic, but some of them should point to this diagnostic possibility.

2020 ◽  
Vol 13 (1) ◽  
pp. 6-15
Author(s):  
Ali El Dirani ◽  
Zahraa Hachem ◽  
Assaad Mohanna ◽  
Amira J. Zaylaa

Introduction: The diagnosis of Central Nervous System Lymphoma, especially the Primary Central Nervous System Lymphoma is carried out based on brain imaging, thus avoiding an unnecessary extend of surgery. But the traditional imaging techniques, such as Computed Tomography and Magnetic Resonance Imaging, were not satisfactory. Aims: This study was conducted to characterize the spectrum of advanced Neuroimaging, such as the advanced Magnetic Resonance Imaging features in the Central Nervous System Lymphoma patients in a comprehensive medical center in Lebanon, and compare them to what has been described in the literature review. Methods: It is a retrospective exploratory study of the clinical data and imaging features for patients admitted to the emergency and radiology departments with ages above 10 years, and who were diagnosed histopathologically with intracranial lymphoma. This study may be the first to make a Radiological evaluation of Central Nervous System Lymphoma on the local population of patients over 9 years . Results: Results showed that the study of the Computed Tomography and Magnetic Resonance Imaging data of 10 immunocompetent patients with Central Nervous System Lymphoma concurs with the previously described patient populations, except for the gender parameter. Tumors were mostly presented in the fifth or Sixth decade and they could be solitary or multi-focal. Lesions were typically located Preprint submitted to The Open Neuroimaging Journal May 14, 2020 in the supratentorial compartment. On the brain Computed Tomography, the lesions were hyperdense, and in pre-contrast Magnetic Resonance images, the lesions appeared hypointense on T1 and hyperintense on T2-Weighted images, but hypointense with respect to the grey matter. The lesions were also surrounded with a mild to moderate edema as compared to other intracranial neoplasms, such as glioblastomas. Evaluation results showed that on post-contrast Magnetic Resonance images, the majority of lesions exhibited a homogeneous enhancement of 50%. Majority of the lesions also showed a less common heterogeneous ring-like enhancement of 40%, and revealed the uncommon absence of enhancement of 10%. Calcifications, hemorrhage, and necrosis were rare findings and were present in only one patient. Conclusion: As a future prospect, studying whether the advanced imaging techniques may provide not only non-invasive and morphological characteristics but also non-invasive biological characteristics and thus accurate diagnosis could be considered.


2007 ◽  
Vol 13 (8) ◽  
pp. 2504-2511 ◽  
Author(s):  
Carole Soussain ◽  
Leslie L. Muldoon ◽  
Csanad Varallyay ◽  
Kristoph Jahnke ◽  
Luciana DePaula ◽  
...  

2021 ◽  
Vol 104 (5) ◽  
pp. 872-885

Fungal infections of the central nervous system (CNS) are usually identified in immunocompromised patients but rare in immunocompetent hosts. The clinical and imaging manifestations are mainly influenced by types of fungal pathogen and immune status of the patients. The CNS fungal infections can develop through hematogenous dissemination from primary site of infection, cerebrospinal fluid seeding, or direct extension from adjacent sources of infection. Fungal infections can result in meningitis, meningoencephalitis, cerebritis, granuloma, or abscess formation, which imaging findings are often non-specific and difficult to distinguish from bacterial or tuberculous infection, non-infectious inflammatory disease, or even intracranial neoplasm. Vascular complications including vasculitis, cerebral infarction, or mycotic aneurysm are commonly present due to angioinvasion of fungal hyphae. In addition, some characteristic imaging features of fungal infections can be identified by computed tomography (CT) or magnetic resonance imaging (MRI), such as intracavitary projections in fungal abscesses and gelatinous pseudocysts in cryptococcosis that could help suggest the diagnosis. Recognizing the imaging findings of common intracranial fungal infections combined with appropriate clinical setting is crucial for allowing early diagnosis and leading to early specific treatment. The present article reviewed common imaging findings of CNS fungal infections and distinct imaging features of specific pathogens. Keywords: Fungal infection, Brain abscess, Cryptococcosis, Central nervous system (CNS), Computed tomography (CT), Diffusion weighted imaging (DWI), Magnetic resonance imaging (MRI)


2017 ◽  
Vol 31 (1) ◽  
pp. 69-82 ◽  
Author(s):  
Cellina Michaela ◽  
Fetoni Vincenza ◽  
Ciocca Matteo ◽  
Pirovano Marta ◽  
Oliva Giancarlo

Myelin oligodendrocyte glycoprotein is a protein exclusively expressed on the surface of oligodendrocytes and myelin in the central nervous system. Antibodies against myelin oligodendrocyte glycoprotein were initially detected in children with demyelinating syndromes, and more recently reported in a broad spectrum of central nervous system demyelinating diseases in adults, including neuromyelitis optica spectrum disorders and bilateral optic neuritis. Patients with myelin oligodendrocyte glycoprotein antibody-associated demyelination appear to have unique clinical and radiological features. To the best of our knowledge a series of Italian patients with optic neuritis and positivity to myelin oligodendrocyte glycoprotein antibodies has not yet been reported and the paper on myelin oligodendrocyte glycoprotein antibodies are more focused on clinical features, diagnosis and outcome than on the radiological appearance, so we want to retrospectively report magnetic resonance imaging features of a group of eight patients, who came to our Ophthalmologic Emergency Department for optic neuritis and were found seropositive for myelin oligodendrocyte glycoprotein antibodies, comparing our data with the findings described in the literature.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4515-4515
Author(s):  
Kristoph Jahnke ◽  
Leslie L. Muldoon ◽  
Csanad G. Varallyay ◽  
Seth J. Lewin ◽  
Robert D. Brown ◽  
...  

Abstract The aim of this study was to determine the efficacy and toxicity of methotrexate (MTX) and/or rituximab treatment in a novel central nervous system (CNS) lymphoma model, using either intravenous (IV) or intraarterial (IA) drug administration in conjunction with osmotic blood-brain barrier disruption (BBBD). Female athymic nude rats (rnu/rnu) were inoculated with human MC116 B-cell lymphoma cells in the caudate putamen. On the day of treatment and first magnetic resonance imaging (MRI) (day 16–20), rats were randomized into 7 groups: control group with saline IV (n = 15) or IA/BBBD (n = 7); rituximab 375 mg/m2 IV (n = 6) or IA/BBBD (n = 3); MTX 1000 mg/m2 IV (n = 6) or IA/BBBD (n = 6); and rituximab 375 mg/m2 IV + MTX 1000 mg/m2 IV (n = 6). A second MRI scan was done 1 week after treatment. Study end points included tumor response on MRI (defined as ≤75% tumor volume on post-treatment MRI), toxicity, and tumor volumes on histology. In the IV groups, the percent change in tumor volume on T2/FLAIR images in the control versus rituximab group was statistically significant (p = 0.0051). In the IA/BBBD groups, there was a statistically significant difference between control and rituximab (p = 0.0167) for absolute and percent changes in tumor volumes on both T2/FLAIR and T1 with gadolinium sequences. For T1 with gadolinium, the difference between control and MTX was also significant for both absolute change (p = 0.0066) and percent change (p = 0.0043). Response rates in the IV groups differed significantly between controls and rituximab (p = 0.0017 on T2/FLAIR and p = 0.0049 on T1 with gadolinium). A good correlation between tumor volumes (in log mm3) on histology and fluid-attenuated inversion recovery (FLAIR)/T2 (R2 = 0.83) or contrast-enhanced T1 weighted images (R2 = 0.73) for tumors located in the caudate putamen was observed. Results of complete blood counts at sacrifice did not differ significantly between the groups. The MC116 CNS lymphoma model is valuable for preclinical testing of efficacy and toxicity of various treatment regimens. Rituximab and MTX were particularly effective in this model, regardless of the route of administration.


Sign in / Sign up

Export Citation Format

Share Document